Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies

Ai Lan Nguyen, Melissa M Gresle, Tessa Marshall, Helmut Butzkueven, Judith Field

Research output: Contribution to journalReview ArticleResearchpeer-review

7 Citations (Scopus)


Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS, and one of the most common causes of disability in young adults. Over the last decade, new disease-modifying therapies have emerged, including monoclonal antibodies (mAbs) that provide highly targeted therapies with greater efficacy than platform therapies. In particular, monoclonal antibodies directed against CD20-positive B cells have shown remarkable results in recent clinical trials and renewed interest in the mechanism of B cell-depleting therapies to ameliorate relapse activity and progression in MS. Here, we review the mechanisms of action and clinical evidence of approved and emerging mAbs, with a focus on B cell-targeted therapies.

Original languageEnglish
Pages (from-to)1895-1907
Number of pages13
JournalBritish Journal of Pharmacology
Issue number13
Publication statusPublished - 1 Jul 2017

Cite this